Study #2022-0446
Phase 2 trial of neoadjuvant and adjuvant Tiragolumab Plus Atezolizumab in patients with newly diagnosed PD-L1 CPS positive resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC)
MD Anderson Study Status
Enrolling
Treatment Agent
Tiragolumab, Atezolizumab
Description
To learn if treatment with tiragolumab and atezolizumab before and after standard of care surgery and chemoradiation (radiation therapy with or without cisplatin/carboplatin) can help to control OCSCC that is PD-L1 CPS positive.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Study phase:
Phase II
Physician name:
Maura Gillison
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-404-4637
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.